- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Krina Patel, MD | Authors
Unmet Needs and Future Perspectives in Multiple Myeloma Treatment
April 21, 2022
A look at the unmet needs and future directions of multiple myeloma treatment.
Novel Agents Under Investigation for Multiple Myeloma
April 21, 2022
Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.
CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies
April 19, 2022
Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.
BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment
April 19, 2022
An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.
Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
April 19, 2022
A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.
Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM
April 19, 2022
A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.
First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial
April 04, 2022
A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.
Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM
April 04, 2022
Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.
Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM
March 25, 2022
A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.
Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials
March 25, 2022
An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.